 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Serono S.A.
 |
Serono S.A. |
 |
 |
 |
PROFILE |
 |
One of the world's biggest biotechnology companies, Serono concentrates on recombinant genetic engineering to develop pharmaceuticals. With operations in 45 countries ranging from marketing to manufacturing to research and development, the company is a leader in reproductive health; flagship drug Gonal-F accounts for more than 30% of Serono's sales. It also focuses on neurological, metabolic, and human growth disorders. Other recombinant products include treatments for multiple sclerosis (Rebif, almost a quarter of sales), growth hormone deficiency, and AIDS-related wasting. CEO Ernesto Bertarelli and his family control Serono.
COMPETITION |
 |
Aventis (AVE)
Biogen, Inc. (BGEN)
Schering-Plough Corporation (SGP)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1,147.00
1-Yr. Sales Growth: 8.8%
Employees: 3,965
Revenue per employee: $289,281.21
KEY PEOPLE |
 |
Ernesto Bertarelli
CEO
Jacques Theurillat
CFO
CONTACT INFO |
 |
Chemin des Mines 15 bis
1211 Geneva 20, Switzerland
Phone: 41-22-739-3000
Fax: 41-22-731-2179
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |